Cargando…
EPCT-03. A PHASE I TRIAL OF 2-HYDROXYOLEIC ACID IN PEDIATRIC PATIENTS WITH ADVANCED CENTRAL NERVOUS SYSTEM TUMORS
2-hydroxyoleic acid (2-OHOA) is the first potential anti-cancer drug to act by modification of cell membrane lipid content. The agent is a derivative of oleic acid, a naturally occurring component of olive oil. Through its unique mechanism of activating sphingomyelin synthase 1, 2-OHOA targets the m...
Autor principal: | Hanson, Derek |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7715915/ http://dx.doi.org/10.1093/neuonc/noaa222.128 |
Ejemplares similares
-
EPCT-08. ACTIVITY OF LAROTRECTINIB IN PEDIATRIC TROPOMYOSIN RECEPTOR KINASE (TRK) FUSION CANCER PATIENTS WITH PRIMARY CENTRAL NERVOUS SYSTEM (CNS) TUMORS
por: Goto, Hiroaki, et al.
Publicado: (2020) -
EPCT-03. Working together to accelerate the preclinical to clinical translation of drug delivery systems for children’s brain tumours
por: Campbell, Emma, et al.
Publicado: (2022) -
EPCT-09. CLR 131 IN PATIENTS WITH RELAPSED OR REFRACTORY PEDIATRIC MALIGNANCIES
por: Puccetti, Diane, et al.
Publicado: (2020) -
EPCT-13. CMV PP65 RNA-PULSED DENDRITIC CELL VACCINES FOR PEDIATRIC GLIOBLASTOMA AND MEDULLOBLASTOMA: PHASE I TRIAL RESULTS
por: Landi, Daniel, et al.
Publicado: (2020) -
EPCT-15. THE REMIND TRIAL: MULTI-ANTIGEN TARGETED T CELLS FOR PEDIATRIC CNS TUMORS
por: Grant, Melanie, et al.
Publicado: (2020)